Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

FDA considering public statement reflecting its view that biosimilars not deemed interchangeable will not be substituted at pharmacy, but the extent such a statement would limit payer-driven practice remains in question.